Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Oncology Drug Shortages Persist, but Continue to Evolve
2.
The diamonds that could find cancer
3.
In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?
4.
Gene therapies for BCG-unresponsive bladder cancer have high response rates.
5.
A paper strip test might enable the early detection of cancer.
1.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
2.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
3.
The Crucial Role of Antithrombin 3 in Preventing Blood Clots: A Comprehensive Guide
4.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
5.
The Importance of Balanced Potassium Levels in Maintaining Good Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge